Piper Jaffray Companies upgraded shares of Genomic Health (NASDAQ:GHDX) from a neutral rating to an overweight rating in a research report report published on Thursday, 24/7 WallStreet reports. Piper Jaffray Companies currently has $72.00 price target on the medical research company’s stock.

A number of other research firms have also recently commented on GHDX. Zacks Investment Research cut Genomic Health from a buy rating to a hold rating in a report on Tuesday, April 23rd. ValuEngine cut Genomic Health from a strong-buy rating to a buy rating in a report on Tuesday, March 5th. Needham & Company LLC reissued a strong-buy rating and set a $97.00 price target (up from $86.00) on shares of Genomic Health in a report on Thursday, February 21st. Deutsche Bank decreased their price target on Genomic Health from $80.00 to $55.00 and set a hold rating on the stock in a report on Thursday, May 30th. Finally, BidaskClub cut Genomic Health from a strong-buy rating to a buy rating in a report on Thursday, February 28th. Nine investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $64.86.

Shares of Genomic Health stock opened at $54.84 on Thursday. Genomic Health has a one year low of $48.72 and a one year high of $92.18. The firm has a market capitalization of $2.03 billion, a P/E ratio of 43.18 and a beta of 1.05. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19.

Genomic Health (NASDAQ:GHDX) last posted its quarterly earnings results on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, beating the Zacks’ consensus estimate of $0.29 by $0.05. The business had revenue of $108.80 million for the quarter, compared to analysts’ expectations of $106.75 million. Genomic Health had a return on equity of 18.70% and a net margin of 10.35%. The business’s quarterly revenue was up 17.5% on a year-over-year basis. During the same period last year, the firm earned ($0.11) earnings per share. As a group, analysts forecast that Genomic Health will post 1.46 earnings per share for the current year.

In other news, CFO G Bradley Cole sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $67.61, for a total transaction of $1,014,150.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bros. Advisors Lp Baker sold 255,970 shares of the firm’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $68.12, for a total value of $17,436,676.40. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 816,063 shares of company stock valued at $53,696,521. Company insiders own 31.30% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. BlackRock Inc. grew its position in shares of Genomic Health by 7.6% during the fourth quarter. BlackRock Inc. now owns 2,191,689 shares of the medical research company’s stock valued at $141,167,000 after purchasing an additional 154,253 shares in the last quarter. Acadian Asset Management LLC grew its position in shares of Genomic Health by 20.5% during the first quarter. Acadian Asset Management LLC now owns 893,114 shares of the medical research company’s stock valued at $62,561,000 after purchasing an additional 151,846 shares in the last quarter. FMR LLC grew its position in shares of Genomic Health by 83.8% during the fourth quarter. FMR LLC now owns 550,627 shares of the medical research company’s stock valued at $35,466,000 after purchasing an additional 251,085 shares in the last quarter. OppenheimerFunds Inc. grew its position in shares of Genomic Health by 30.0% during the first quarter. OppenheimerFunds Inc. now owns 469,560 shares of the medical research company’s stock valued at $32,893,000 after purchasing an additional 108,337 shares in the last quarter. Finally, Clearbridge Investments LLC grew its position in shares of Genomic Health by 21.6% during the first quarter. Clearbridge Investments LLC now owns 340,847 shares of the medical research company’s stock valued at $23,876,000 after purchasing an additional 60,432 shares in the last quarter. Hedge funds and other institutional investors own 95.54% of the company’s stock.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Featured Story: Percentage Gainers

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.